P-019 Cytotoxic CD4+ T cells are major drivers of side effects and response after chimeric antigen receptor T cells against BCMA

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01922-0

David Fandrei, Michael Rade, Markus Kreuz, Luise Fischer, Patrick Born, Sabine Seiffert, Andreas Boldt, Jonathan Scolnick, Lakshmi Venkatraman, Stacy Xu, Ronny Baber, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Klaus H. Metzeler, Marco Herling, Madlen Jentzsch, Carmen Herling, Georg-Nikolaus Franke, Ulrike Köhl, Maximilan Merz

引用次数: 0

查看原文本刊更多论文

P-019 细胞毒性 CD4+ T 细胞是嵌合抗原受体 T 细胞抗 BCMA 副作用和反应的主要驱动因素

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.